

# C4 & C6-enriched triglycerides increase postprandial circulating levels: a randomized trial

K Lemmens<sup>1</sup>, TM van Deuren<sup>2</sup>, L Smolders<sup>1</sup>, A Hartog<sup>1</sup>, FG Bouwman<sup>2</sup>, JJ Holst<sup>3,4</sup>, K Venema<sup>5</sup>, EE Blaak<sup>2</sup> & EE Canfora<sup>2</sup>

<sup>1</sup>R&D Health sciences, AAK, Zaandijk, The Netherlands  
<sup>2</sup>Dept of Human Biology, School for Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht University Medical Center+, Maastricht, The Netherlands  
<sup>3</sup>Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark  
<sup>4</sup>Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark  
<sup>5</sup>Centre for Healthy Eating and Food Innovation, Maastricht University, Venlo, The Netherlands

## Background

Short Chain Fatty Acids (SCFA) are produced by the gut microbiome. They are linked to various health benefits (Fig 1)<sup>1</sup>.




Figure 1: Health benefits SCFA, adopted from Xiong et al., 2022

A diet low in fibers or an unhealthy microbiome results in limited SCFA production in the gut and reduced availability in the circulation. SCFA absorption is important for metabolic effects. Consumption of SCFA may therefore provide a valuable strategy to combat metabolic diseases<sup>2,3</sup>. A structured triglyceride containing butyrate (C4) and hexanoate (C6) was developed aiming to improve absorption and metabolic effects.

## Aim

To evaluate whether orally administrated C4 & C6-enriched triglycerides increase C4 and C6 levels in the circulation.

## Methods

In a double-blind placebo-controlled crossover study, 12 overweight/obese men consumed a liquid high fat mixed meal containing either control (high oleic sunflower oil) or a low (650 mg), medium (1325 mg) or high dose (2000mg) of C4 & C6-enriched triglycerides. Blood was sampled at baseline and after ingestion for 6h. Primary outcomes; plasma C4 and C6 concentration. Secondary outcomes; gastrointestinal tolerance and metabolic markers.




Figure 2: Example of study design. Each participant was randomized for the order in which they received the dose, with a washout period of 1-4 weeks

## Conclusion

An acute dose of C4 & C6-enriched triglycerides was well tolerated and increased postprandial circulating C4 and C6 levels. Future research is needed to investigate the long-term effects of the C4 & C6-enriched triglyceride.

## Results & discussion

Orally administrated C4 & C6-enriched triglycerides increased total circulating C4 and C6 levels for low, medium and high dose (iAUC<sub>0-6h</sub>) (Fig 3). The medium dose resulted in the highest absorption, indicating an optimal dose.




Figure 3: The effect of C4 & C6-enriched triglycerides on postprandial circulating SCFA: C4 (A, B) and C6 (C, D) concentrations. iAUC: incremental area under the curve. Graphs indicate means  $\pm$  SEM,  $p^* < 0.05$ ,  $p^{**} < 0.01$

The C4 & C6-enriched triglycerides were well-tolerated (Fig 4).




Figure 4: The effect of C4 & C6-enriched triglycerides on gastrointestinal complaints assessed by a gastrointestinal symptom rating scale. Postprandial GRS scores (t0-t360 min) indicated on a Likert scale after ingestion of C4 & C6-enriched triglycerides for: abdominal pain (A), abdominal discomfort (B), bloating (C) and nausea (D). Graphs indicate means  $\pm$  SEM

An acute dose of C4 & C6-enriched triglycerides did not result in significant effects on metabolic markers; glucagon-like peptide 1, glucose, insulin, triglyceride and cytokines (data not shown).